Efficiency of stroke clinical trials with ordinal outcomes: a simulation study UPC, Julio 2010 BASEL, October 2011 Juan Vicente Torres Supervisors: Dr.

Slides:



Advertisements
Similar presentations
3/28/2017© 2009, American Heart Association. All rights reserved.
Advertisements

Phase II/III Design: Case Study
ASSESSING RESPONSIVENESS OF HEALTH MEASUREMENTS. Link validity & reliability testing to purpose of the measure Some examples: In a diagnostic instrument,
Study Design 121 Relapsing-remitting MS patients randomized to –Stress Management Therapy MS active treatment* 16 individual sessions conducted over 24.
TPA in Stroke: What's All the Fuss?. FERNE Brain Illness and Injury Course.
New England Journal of Medicine October 18;367: Relapse Risk after Discontinuation of Risperidone in Alzheimer’s disease Molly Moncrieff.
The NINDS rt-PA Stroke Trial Prior information(Pre-Clinical, Phase I Studies, etc) Thrombolytic canalization of occluded arteries may reduce the degree.
Departments of Medicine and Biostatistics
FACTORS HINDERING ATTITUDE TO TREATMENT AMONG PATIENTS WITH TYPE-2 DIABETES MELLITUS IN THE NIGER DELTA, NIGERIA by AGOFURE OTOVWE and OYEWOLE OYEDIRAN.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
The Cost-Effectiveness of Providing DAFNE to Subgroups of Predicted Responders J Kruger 1, A Brennan 1, P Thokala 1, S Heller 2 on behalf of the DAFNE.
Is low-dose Aspirin use associated with a reduced risk of colorectal cancer ? a QResearch primary care database analysis Prof Richard Logan, Dr Yana Vinogradova,
Journal Club Alcohol, Other Drugs, and Health: Current Evidence May–June 2013.
© Nancy E. Mayo 2004 Sample Size Estimations Demystifying Sample Size Calculations Graphics contributed by Dr. Gillian Bartlett.
© 2005 The McGraw-Hill Companies, Inc., All Rights Reserved. Chapter 13 Using Inferential Statistics.
TPA in Acute Ischemic Stroke: The NINDS Reanalysis & Meta-analysis Data Sidney Starkman, MD, FACEP.
Andrew Asimos, MD, FACEP Stroke Patient and Stroke Therapies Assessment: ED NIHSS & Stroke Scales Use for ED Stroke Therapies.
T-PA in Treatment of Acute Stroke: What We Know From NINDS 2004 vs 2000 Sidney Starkman, MD Departments of Emergency Medicine and Neurology, UCLA UCLA.
FERNE/MEMC Session: Treating Ischemic Stroke in the 3 – 4
Linear Regression and Correlation Explanatory and Response Variables are Numeric Relationship between the mean of the response variable and the level of.
Comorbidity in SLE Compared with Rheumatoid Arthritis and Non-inflammatory Disorders Frederick Wolfe 1, Kaleb Michaud 1,2, Tracy Li 3, Robert S. Katz 4.
Study Design / Data: Case-Control, Descriptives Basic Medical Statistics Course: Module C October 2010 Wilma Heemsbergen
Stroke,Past,Present, Future. Impact of stroke 1,2 Stroke has a major impact on people’s lives Stroke is the: –single most devastating effect of hypertension.
Abstract Tooth loss data from 100 periodontal patients (2509 teeth) under maintenance care for up to 15 years were analyzed to develop a system for determination.
Seminar, Bordeaux School of Public Health 8 June 2011 Combining endpoints in clinical trials to increase power John Whitehead Medical and Pharmaceutical.
Using stroke scales to assess the patient – Rankin and NIHSS
Research Study Design and Analysis for Cardiologists Nathan D. Wong, PhD, FACC.
Quality Measures for Rehabilitation: Policy, Provider and Patient Perspectives Measuring Clinical Change: Quality Indicators ACRM-ASNR Pre-Conference Institute.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar Dr.PH. Batch 5 1.
MODEGAT Chalmers University of Technology Use of Latent Variables in the Parameter Estimation Process Jonas Sjöblom Energy and Environment Chalmers.
Background to Adaptive Design Nigel Stallard Professor of Medical Statistics Director of Health Sciences Research Institute Warwick Medical School
Systematic Reviews.
Perceived Recovery as a Predictor of Physical Activity after Mild Stroke Jessica Koster, BA, MSOTS 1, & Timothy J. Wolf, OTD, MSCI, OTR/L 1,2 Washington.
Association between Response time and Mortality in Drowning Patients in Thailand Mr.Phichet Nongchang Dr PH Faculty of Public Health, Khon.
Tissue Plasminogen Activator for Acute Ischemic Stroke National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group.
EBC course 10 April 2003 Critical Appraisal of the Clinical Literature: The Big Picture Cynthia R. Long, PhD Associate Professor Palmer Center for Chiropractic.
Validation / citations. Validation u Expert review of model structure u Expert review of basic code implementation u Reproduce original inputs u Correctly.
Logistic and Nonlinear Regression Logistic Regression - Dichotomous Response variable and numeric and/or categorical explanatory variable(s) –Goal: Model.
Association between Systolic Blood Pressure and Congestive Heart Failure Complication among Hypertensive and Diabetic Hypertensive Patients Mrs. Sutheera.
RMH Comprehensive Stroke Centre Thrombolysis and Stroke Units : The Evidence Professor Stephen Davis Royal Melbourne Hospital Comprehensive Stroke Centre.
RevMan for Registrars Paul Glue, Psychological Medicine What is EBM? What is EBM? Different approaches/tools Different approaches/tools Systematic reviews.
Applying meta-analysis to trauma registry Ammarin Thakkinstian, Ph.D. Clinical Epidemiology Unit Faculty of Medicine, Ramathibodi Hospital Tel: ,
Lecture 9: Analysis of intervention studies Randomized trial - categorical outcome Measures of risk: –incidence rate of an adverse event (death, etc) It.
Risk assessment for VTE Dr Roopen Arya King’s College Hospital.
Evaluating Risk Adjustment Models Andy Bindman MD Department of Medicine, Epidemiology and Biostatistics.
ASSOCIATION BETWEEN ABDOMINAL COMPLAINTS AND NARCOTIC USE AMONG PATIENTS WITH SHORT BOWEL SYNDROME RECEIVING TEDUGLUTIDE Ken Fujioka, 1 Khursheed Jeejeebhoy,
Assessing Responsiveness of Health Measurements Ian McDowell, INTA, Santiago, March 20, 2001.
Ebrictus Register St Coordination Strategies of Care across Stroke recovery: Proposals for Nursing Intervention in Primary Care Teresa Forcadell-Arenas.
NODE 0 mRS 0: 13.6% (n=551) mRS 1: 19.4% (n=785) mRS 2: 14.7% (n=597) mRS 3: 16.5% (n=668) mRS 4: 21.1% (n=855) mRS 5: 7.0% (n=324) mRS 6: 6.7% (n=271)
Association between Response time and Mortality in Drowning Patients in Thailand Mr.Phichet Nongchang Dr PH Faculty of Public Health, Khon.
MR CLEAN Multicenter Randomized CLinical Trial of Endovascular Treatment of Acute Ischemic Stroke in the Netherlands C.B. Majoie, Y.B. Roos, A. van der.
Long-Term Outcomes after Acute Stroke Treatment Larry B. Goldstein, M.D. Professor of Medicine (Neurology) Center for Cerebrovascular Disease Center for.
REGRESSION MODEL FITTING & IDENTIFICATION OF PROGNOSTIC FACTORS BISMA FAROOQI.
Sanaz Sakiani, MD Endocrinology Fellow Journal Club
PHARMAECONOMICS Pulmonary Arterial Hypertension Nelli ÄIJÖ & Feyza Nur POLAT Nika Marđetko.
J Clin Oncol 30: R2 윤경한 / Prof. 김시영 Huan Jin, Dongsheng Tu, Naiqing Zhao, Lois E. Shepherd, and Paul E. Goss.
Keystone Heart Reflect Neurology
Global burden of diseases
Siriporn Poripussarakul, Mahidol University, Thailand
Applied Biostatistics: Lecture 2
mRS & NIHSS Training and Certification Procedure
Dose-finding designs incorporating toxicity data from multiple treatment cycles and continuous efficacy outcome Sumithra J. Mandrekar Mayo Clinic Invited.
Annals of Internal Medicine • Vol. 167 No. 12 • 19 December 2017
Three outcome measures from the NINDS tPA trial
National Institutes of Health Stroke Scale (NIHSS) scores were evaluated as a measure of neurological deficit in patients within 30 days, and the Barthel.
Additional efficacy outcomes for the 12-week study of Japanese patients with rheumatoid arthritis treated with baricitinib or placebo. Additional efficacy.
Josep M. Llovet, Robert Montal, Augusto Villanueva 
Post-Acute Follow-Up Helps Track Patient Outcomes
National Institutes of Health Stroke Scale (NIHSS) scores were evaluated as a measure of neurological deficit in patients within 30 days, and the Barthel.
Björn Bornkamp, Georgina Bermann
Presentation transcript:

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study UPC, Julio 2010 BASEL, October 2011 Juan Vicente Torres Supervisors: Dr. Julio Secades Dr. Erik Cobo

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study 2/24 Content Introduction Methods –Patients –Treatment effect imputation –Assessed methods Results Conclusions

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study INTRODUCTION 3/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study Stroke is the second most common cause of death and a major cause of disability worldwide. Although at least 178 randomized clinical trials were conducted for 75 promising agents, only 1 agent has been approved by the FDA/EMA (2001). 4/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study The gold standard for performing Phase III clinical trials has been to dichotomize the mRS as a good outcome (scores 0 or 1): 5/ No symptoms. 1 - No significant disability. Able to carry out all usual activities 2 - Slight disability. Able to look after own affairs without assistance 3 - Moderate disability. Requires some help 4 - Moderately severe disability. Needs assistance 5 - Severe disability. Requires constant care and attention 6 - Dead.

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study Different alternatives have been proposed: 1.Shift Analysis [Savitz et al, 2007]: –Works with the full ordinal scale 2.Responder analysis [Berge et al, 2002]: –Dichotomizes the outcome taking into account the initial status of each patient. 3.Global recovery outcome [Dávalos, 2002]: –Considers simultaneously information from more than one recovery dichotomized variables. 6/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study Objective: To assess the power of the most common statistical methods used in stroke clinical trials and other alternatives. 7/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study METHODS 8/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study Scales The modified Ranking Scale (mRS): –Measures disability or dependence in daily activities. –from 0 (perfect health) to 6 (death). The National Institute of Health Stroke Scale (NIHSS) –Measures neurological status. –from 0 (minimal) to 42 (severe deficit). The Barthel Index (BI) –Measures independence in personal care and mobility. –from 0 to 100 (independence) by steps of 5. –It was transformed as iBI = (100-BI)/5. 9/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study Data Pooling database grouping 4 clinical trials performed to assess the efficacy of oral citicoline. Applying new eligibility criteria, 1372 patients were selected, 789 randomized to citicoline and 583 to placebo. Only placebo data was employed in the simulations. 10/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study Addition of the treatment effect Using two different strategies: –Partial (or patient) level: OAST collaboration, 2008 –Marginal (or population) level: Choi et al, 1998 OR=1.20, 1.25, 1.30 and 1.35 ORs under an ordinal logistic regression (proportional odds) 11/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study Partial level 12/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study Marginal level 13/24 Based on an ordinal logistic regression model, a treatment effect is added redistributing the patients within the scores

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study 14/24 Example:

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study Statistical methods to assess treatment effect Dichotomized mRS: mRS≤1 and mRS≤2. Full ordinal scale: t-test, Wilcoxon-Mann-Whitney test, ordinal logistic regression with proportional odds. Responder analysis as proposed by Adams et al. (2004) and Murray et al. (2005) A global ad-hoc version of the above methods is employed. The effect of adjusting for important prognostic variables in each method is also assessed. 15/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study Power and alpha estimation The power was obtained as the percentage of significant results over 10,000 iterations. 16/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study RESULTS 17/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study 18/24 Partial level Marginal level mRS before the treatment effect addition mRS after adding the treatment effect OR = OR =

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study 19/24 Partial level Marginal level Correlations between the original and simulated outcomes

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study 20/24 Power comparison

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study 21/24 Power comparison Marginal level scenario

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study CONCLUSIONS & LIMITATIONS 22/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study Conclusions In Stroke trials, the analysis of ordinal scales might be improved by –taking into account the ordinal characteristic of the scales, –adjusting by prognostic variables, –incorporating information of other scales. Need to define a formal method to incorporate these three factors 23/24

Efficiency of stroke clinical trials with ordinal outcomes: a simulation study 24/24 Thanks!!